SUTRO BIOPHARMA, INC. Cash and Cash Equivalents, Period Increase (Decrease)
SUTRO BIOPHARMA, INC. (STRO) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$105.91 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-08-14.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-08-14
- SUTRO BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was -$7.23M, a 138.46% decline year-over-year.
- SUTRO BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$98.68M.
- SUTRO BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $83.94M.
- SUTRO BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $15.93M.
- SUTRO BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $103.28M, a 915.82% increase from fiscal 2017.
- SUTRO BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $10.17M.
- SUTRO BIOPHARMA, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$3.38M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-06-30 | -$7.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$105.91M 10-Q · filed 2019-08-14 | -$21.96M derived: sum of 3 quarters · filed 2019-08-14 | -$6.03M derived: sum of 4 quarters · filed 2019-08-14 |
| 2019-03-31 | -$98.68M 10-Q · filed 2019-05-15 | -$14.74M derived: sum of 2 quarters · filed 2019-05-15 | $1.20M derived: sum of 3 quarters · filed 2019-05-15 | $19.98M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-12-31 | $83.94M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $99.88M derived: sum of 2 quarters · filed 2019-04-01 | $118.67M derived: sum of 3 quarters · filed 2019-08-14 | $103.28M 10-K · filed 2019-04-01 |
| 2018-09-30 | $15.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $34.72M derived: sum of 2 quarters · filed 2019-08-14 | $19.33M 10-Q · filed 2018-11-14 | $15.95M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-06-30 | $18.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $3.40M 10-Q · filed 2019-08-14 | $13.00K derived: sum of 3 quarters · filed 2019-08-14 | |
| 2018-03-31 | -$15.39M 10-Q · filed 2019-05-15 | -$18.77M derived: sum of 2 quarters · filed 2019-05-15 | ||
| 2017-12-31 | -$3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $10.17M 10-K · filed 2019-04-01 | ||
| 2017-09-30 | $13.55M 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | -$3.38M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |